Condition: Glioma · Sponsor: Central Hospital, Nancy, France
the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis
This description comes directly from the study's public registry record.
VERONIQUE ROCH, MSc · 0383154276 · v.roch@chru-nancy.fr
ANTOINE VERGER, MD, PhD · 0383155567 · a.verger@chru-nancy.fr
Always discuss trial participation with your own doctor first.
| CHRU Nancy | Vandœuvre-lès-Nancy, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05512403